EGFR and neoplasm: Moreover, it has been shown that patients with EGFR mutations have fewer T cell infiltrations of PD-L1+/CD8+ tumor infiltrating lymphocytes (TILs) and reduced shrinking properties of the tumor in response to immune cell activation (Figure 2C, Dong et al., 2017a).